Chemistry, manufacturing, and controls strategies for antibody-targeted lipid nanoparticles
BME Horizon · 2024
DOI: 10.70401/bmeh.2026.0022 ↗Kurz gefasst
Fachartikel in der Zeitschrift BME Horizon, 2024. Verfasst von Ri Huang und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Antibody-targeted lipid nanoparticles (Ab-LNPs) represent a highly promising delivery platform for precision therapy, enabling efficient in vivo targeted delivery of nucleic acid drugs such as mRNA, DNA and siRNA. Currently, the two primary strategies for antibody functionalization of LNPs are the post-insertion method and direct surface conjugation. This review outlines the key chemistry, manufacturing, and controls challenges associated with scaling up of Ab-LNP production, with a focus on antibody modification strategies, process scale-up challenges, and quality control considerations. It aims to provide practical guidance for translating Ab-LNP technology from laboratory research to scalable manufacturing.
Zitieren
APA
Huang, R., Wang, Y., Shi, T., Piao, X., Ren, K., Deng, C., & Xu, C. (2024). Chemistry, manufacturing, and controls strategies for antibody-targeted lipid nanoparticles. BME Horizon. https://doi.org/10.70401/bmeh.2026.0022
Vancouver
Huang R, Wang Y, Shi T, Piao X, Ren K, Deng C, et al. Chemistry, manufacturing, and controls strategies for antibody-targeted lipid nanoparticles. BME Horizon. 2024. doi:10.70401/bmeh.2026.0022
BibTeX
@article{Huang2024,
author = {Huang, Ri and Wang, Yifan and Shi, Tianyu and Piao, Xijun and Ren, Keyun and Deng, Changchang and Xu, Congcong},
title = {Chemistry, manufacturing, and controls strategies for antibody-targeted lipid nanoparticles},
journal = {BME Horizon},
year = {2024},
doi = {10.70401/bmeh.2026.0022}
}
EUVIMED